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Background: The city of San Francisco boasts a high rate of hepatitis C infection (HCV) among 
IV drug users indicating the need for a hepatitis C treatment program. It is estimated that over 
two-thirds of people who are actively infected with HCV are IV drug users (EndHepCSF, 2017), 
and in 2017 the San Francisco Department of Public Health (SFDPH) estimated that there are 
22,500 active people who inject drugs (PWID) in SF (SFDPH, 2017). With the presence of a 
wide population of IV drug users in SF there is an identified need for intervention to treat this 
high-risk patient population. 
Methods: After identification of a significant population of HCV infected patients in a 
community clinic, the latest evidence for HCV treatment was used to develop and pilot a 
practical HCV treatment program using glecaprevir/pibrentasvir (Mavyret). The pilot was aimed 
at testing a protocol in primary care, utilizing evidence based strategies. 
Results:   A total of 6 patients were enrolled in the pilot. There was a successful response rate 
(100% SVR) among the treatment group, supporting the use of single drug treatment with 
observed therapy in high risk populations.  
Conclusion: The results of the project demonstrated that a standardized hepatitis C treatment 
program is highly efficacious and can be delivered in primary care settings to patients who are 
high risk. 
 
Keywords:  HCV, PWID, barriers, adherence, treatment, recommendations, education, 
awareness, resources, increase rates.   
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SECTION II: Introduction 
Background/Knowledge 
Hepatitis C virus (HCV) is the most common chronic blood-borne disease in the United 
States. HCV is a chronic RNA virus that causes progressive liver damage, and is the leading 
cause (Razavi et al., 2013) of liver cirrhosis, hepatocellular carcinoma (liver cancer), and liver 
transplantation (Manns, et al., 2017). Patients who are at higher risk of being infected are: people 
who inject drugs (PWID) (accounting for over half of the active HCV population), men who 
have sex with men (MSM), and baby boomers (EndHepCSF, 2017). Other high risk groups are 
people with prior injection use, people living with HIV, transgender women, and people with a 
history of incarceration (EndHepCSF, 2017). HCV is transmitted through contact with 
contaminated blood of an infected person. Modes of transmission are contact with infected 
needles (more common in the healthcare setting), tattoos or body piercings using non-sterile 
tools, current or past IV drug use (sharing needles), blood transfusions or organ transplants 
before 1992, and contaminated equipment and needles used for dialysis in the healthcare setting 
(Gilead, 2015). Symptoms of HCV include fever, fatigue, loss of appetite, nausea and vomiting, 
abdominal pain, dark urine, gray-colored bowel movements, joint pain and jaundice (yellow hue 
of skin). HCV symptoms may not appear for years, or even decades. Even though the patient 
may not feel sick, HCV can be silently doing harm (Gilead, 2015). HCV was once without a 
cure, but recognition that HCV is a treatable, curable, and a preventable disease, and that 
treatment can reduce healthcare costs of the comorbidities that are associated with HCV, such as 
liver cirrhosis and cancer, have changed this belief. Cured HCV is represented by a sustained 
virologic response (SVR) of the patient, measured 12 weeks after treatment completion (known 
as SVR12). Most recently the development of treatments has successfully demonstrated a cure 
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for this virus and the possibility of avoiding long term consequences. On a global level, between 
64 and 103 million people are chronically infected with HCV (Manns, et al., 2017). In the U.S., 
HCV affects over 3 million people (Gilead, 2015), and has surpassed all other nationally 
notifiable infectious diseases combined as a cause of death in the U.S. (EndHepCSF, 2017). 
There is an estimated 12,000 people living with active HCV in SF (EndHepCSF, 2017), 
indicating there is a continuing need for HCV awareness, education, and treatment in 
communities.   
HCV was discovered 30 years ago in 1989 by scientists at the Centers for Disease 
Control and Prevention (CDC), National Institutes of Health (NIH) and industry (CDC, 2014). In 
1991, the Food and Drug Administration (FDA) approved the very first drug to treat HCV (CDC, 
2014). Unfortunately, the initial treatment resulted in very few patients clearing the virus (CDC, 
2014). Since 1991, a total of 16 antiretroviral medications (two of which have been removed 
from the market) have been developed (Spach & Kim, 2018), leaving 14 currently active HCV 
drugs on the market. The medications initially used to treat HCV were combinations of ribavirin 
and interferon and had many side effects, such as nausea and vomiting, weight loss, depression, 
insomnia, flu-like symptoms, diarrhea, headache, malaise, joint and muscle pain, and exhaustion 
(Wessels, 2018). Over the course of time, the medications to treat HCV have established a lower 
side effect profile, and have gone from combination drug treatments to single drug treatments, 
like Mavyret. Mavyret belongs to a new class of direct acting antivirals (DAA) for HCV, and is 
regarded as being very cost-effective, having the best tolerance and treatment adherence rates 
due to the low side-effect profile, and is able to treat all six genotypes. The newer treatment 
options are very promising, but also come at an incredibly high cost to the health care system. In 
February 2017, 29% of San Francisco Health Plan’s (SFHP) pharmacy budget (representing only 
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0.2% of pharmacy claims) was used for Hepatitis C treatment (San Francisco Hepatitis C Task 
Force, 2017). Since HCV is a particularly outstanding health care problem in SF due to a higher 
population of high-risk patients (EndHepCSF, 2017).  
Of the 3 million people in the U.S. who are actively infected with HCV, PWID make up 
68% of that population (EndHepCSF, 2017). Since PWID makes up a very large percentage of 
the HCV population, it is important that this specific patient population be treated and not turned 
away from receiving care and treatment. In the past, this specific patient population had been 
turned aware from receiving HCV treatment due to patient fear of stigmatization by providers 
and society, provider fear that the patient would not complete treatment, and provider concerns 
that patients would reinfect themselves after being cured, indicating it would be a waste of 
resources to treat PWID (Grebely, Oser, Taylor & Dore, 2013). When this patient population is 
left untreated healthcare costs and demands increase in other ways due to hepatic and non-
hepatic comorbidities, which include insulin resistance, cryoglobulinemia, dermatologic disease, 
renal disease, cardiovascular disease, and chronic fatigue (EndHepCSF, 2017). According to End 
Hep C SF (2017), the benefits of HCV treatment are a 90% risk reduction in liver transplant and 
liver-related mortality, a 70% decrease in liver cancer, and 50% of patients who have liver 
cirrhosis will have improvement in their fibrosis. The estimated costs of comorbidities in the US 
associated with HCV (liver cirrhosis, hepatocellular carcinoma, liver failure, and liver 
transplants) is $6.5 billion per year and will peak in 2024 to $9.1 billion (Razavi et al., 2013). 
Razavi et al. (2013) states it is possible to reduce HCV infection and, in turn, the costs of 
comorbidities associated with HCV through active management of this viral infection. The 
initiation of HCV treatment in PWID is overall more cost-effective and can prevent further liver-
related mortality when treated in the early stages (EndHepCSF, 2017).  
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Various direct-acting antivirals (DAAs) have been approved by the FDA and are 
available on the market. DAAs target three proteins involved in the HCV life cycle: the NS3/4A 
protease, the NS5A protein, and the RNA-dependent RNA polymerase NS5B protein. A 
combination of two or three of these medications can cure HCV in >90% of patients, including 
patients who have been difficult to treat in the past (Manns, et al., 2017). In 2013, Sovaldi was 
one of the first new HCV drugs, also classified as a direct acting anti-viral, that was approved by 
the FDA. The listing price for Sovaldi was $84,000 for a 12-week treatment, but the price has 
since come down due to public health programs, like Medi-Cal, being able to negotiate the cost. 
In more recent years, the HCV drug Zepatier, costing $54,600 for a course of treatment, and 
Mavyret, costing $26,400, are similar to Solvadi, Harvoni, and Viekira Pak in that they have 
fewer side effects, work faster, and are more effective in curing HCV than the older HCV drug 
interferon (Bartolone, 2018). The total cost of Mavyret has been priced by AbbVie (the 
manufacturer of Mavyret) for $13,200 per month, or $26,400 per eight-week course of treatment 
for each patient (Shye, 2017).  
Table 1 
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According to the U.S. Census conducted in 2015, 2.5% of all people living in SF have 
HCV (EndHepCSF, 2017). Among this percentage, 68% of the active cases are made up by 
people who inject drugs, 14% by men who have sex with men, and baby boomers make up the 
other 38% (EndHepCSF, 2017). The estimated percentage of people living with HCV in SF 
(2.5%) is significantly higher than the national percentage of 1.7% (EndHepCSF, 2017). It is not 
a surprise since that the burden of HCV disease is greater in SF since a higher proportion of the 
residents of the city are in the groups at highest risk for HCV. San Francisco has the highest liver 
cancer rate in the nation, most of which is attributed to high rates of Hepatitis B and C virus 
infections (San Francisco Hepatitis C Task Force, 2017).   
Gap Analysis 
 A gap analysis was conducted in the city of San Francisco at a local community clinic 
that serves a significant population of PWID and are considered at higher risk for contracting 
HCV. A comparison of the current state to the desired future state was done in order to determine 
what was needed to achieve the prospective goal (Appendix C). According to McGown and 
Fried (2011), these high-risk populations often do not seek treatment for several reasons. 
Mentioned reasons include: poor awareness/education, lack of interest in seeking treatment 
since they are asymptomatic, lack of medical coverage, failure of the provider to screen 
the patient, patient non-adherence to the medication regimen, provider failure to refer the 
patient, limited specialist availability (patients who present with a more complicated 
clinical picture such as liver cirrhosis), patient fears and misunderstandings, 
stigmatization, substance abuse, transportation challenges, and communication 
difficulties (no cell phone and/or reliable address).  
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The most common concern seen in patients that hindered their interest in receiving 
HCV care and treatment was the side effects they could encounter with the medication. 
The next most common identified gap was patients did not feel they need to be treated for 
HCV if they were asymptomatic. These concerns were addressed during their primary 
care visits with the providers at to provide education that the newer HCV medications, 
such as Mavyret, have minimal to no side effects, and that even though they may feel 
healthy right now, the HCV is actively causing harm to their liver, and by the time 
symptoms are experienced damage has already been done.  
Setting 
BAART Programs for the treatment of opioid addiction and primary care are nationwide 
group of community health centers with a total of 29 locations (BAART, 2019). BAART Turk is 
a California Community Clinic and is a member of the San Francisco Community Clinic 
Consortium (SFCCC). Six of the BAART locations are in the San Francisco Bay Area (BAART, 
2019). The populations served are people recovering from substance abuse and pursuing to 
achieve life-time recovery, and underserved populations (low-income and/or homeless residents 
of the surrounding area). BAART provides substance use counseling, the initiation, maintenance, 
and monitoring of methadone and buprenorphine administration, and low-cost primary care and 
preventive health services. Opioid use disorder treatment, and mental health and primary care 
services are offered in one convenient location at BAART on Turk Street (BAART Turk) 
(BAART, 2019). Of the 400-600 patients who are dosed daily for methadone, 115 of these 
patients are eligible to be treated for HCV. Currently, there are a total of 35 staff at BAART 
Turk. The staff consist of: one medical assistant who performs lab draws, takes patient vital 
signs, gives injections, rooms patients, and performs nebulizer and wound care treatments; three 
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registered nurses who dispense medications to patients; 14 substance abuse counselors; two 
nurse practitioners (NPs) and two physicians for provider appointments; two front desk 
receptionists to check-in patients; two counseling supervisors; one on-site clinic director; one 
mental health director; one psych NP; one mental health nurse; four interns either training to be 
mental health counselors or doing their one-year internship for a PsyD program; one 
administration assistant; and one security guard. The insurances that are accepted at BAART 
Turk are Anthem Blue Cross of California, Medi-Cal, private insurance (Anthem Blue Cross, 
Kaiser Permanente, Veterans, and other private insurance with pre-authorization), and TriWest 
(Health Net Federal Services), and San Francisco Health Plan (SFHP) (BAART, 2019).  
BAART Turk Street Clinic is well positioned to contribute to the treatment and 
eradication of HCV in PWID. According to the San Francisco Department of Public Health 
(SFDPH) (2017), 31% of the 22,500 people who are active IV drug users in SF reside in the 
Tenderloin, making the location of this clinic in the heart of the Tenderloin very convenient and 
has proven to be highly effective in treating this patient population. BAART Turk has a large 
patient population who is at risk for having and transmitting HCV (EndHepCSF, 2016).  
Majority of patients seen at BAART Turk are there to receive methadone treatment. The 
patients usually come in for their medication daily and it is distributed to them by the nursing 
staff. There are a total of two physicians and two nurse practitioners on site who see patients for 
both primary care and specialized methadone care. When BAART Turk did not have a HCV 
treatment protocol, they reached out to the San Francisco Health Plan (SFHP) and created a 
partnership to receive a grant for the treatment of infected individuals over the next two years. It 
was projected that the HCV grant would provide treatment to hundreds of high-risk patients by 
September 2018, and will achieve a cure for 85% of participating patients by the year 2020 
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(Kletter, 2018). The grant indicated that the antiretroviral Mavyret be used for the treatment of 
HCV at BAART Turk due to its low side-effect profile, ability to treat all genotypes, and low-
cost compared to other HCV treatment medications on the market (Abbvie, 2018). Costs of 
Mavyret were covered by the grant. The stakeholders of the project are Dr. Deb Borne (chief 
organizer, lead physician), Dr. Brian Clear (project oversight as the medical director of BAART 
Turk), Cara Nalagan, NP (project coordinator, lead NP), and Annie Pedlar, NP student intern as 
the DNP author. The intervention is applicable to the patients at BAART due to the high-risk 
profile of patients with homelessness and IV drug abuse (IVDA). The implementation of the 
HCV treatment program at BAART Turk was authorized by the San Francisco Department of 
Public Health (SFDPH), SFHP, and by the medical director, Dr. Brian Clear, of BAART Turk. 
The collaboration between USF and BAART Turk was developed through a memorandum of 
understanding (MOU), and the project proposal, as stated in the statement of determination 
(Appendix A) was approved by committee chair, Dr. Prabjot (Jodie) Sandhu and my role as DNP 
author was authorized by Dr. Brian Clear, medical director of BAART Turk who has written a 
letter of support (Appendix B).  
BAART would like to support efforts to target hard-to-reach populations, such as those 
who use IV drugs and/or with unstable housing, to improve treatment efficacy, and secondarily 
reduce rates of Hepatitis C transmission in SF. Since their patient population is high-risk for 
having and becoming infected with HCV, the implementation of a HCV treatment program 
would largely benefit the primary care and methadone patients seen at BAART. 
Need for Evidence Based Intervention 
Due to its strength in treating HCV regardless of genotype, accessibility, low side effects, 
and short treatment period, the treatment of HCV with Mavyret is highly recommended as a first-
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line choice drug for high-risk populations. Given that Mavyret is highly efficient and effective, it 
is an ideal treatment model and the best drug choice for a HCV treatment plan or protocol in a 
community setting.  
Search Process 
A systematic search was conducted in June-September 2018 based on the PICO question: 
In patients with active hepatitis C virus (HCV), will treatment with the antiviral medication such 
as glecaprevir/pibrentasvir (Mavyret) compared to no treatment result in a cure rom HCV, 
demonstrated by attaining a sustained virologic response (SVR). Furthermore, investigation of 
best practices and research related to evaluate the cost of HCV drugs and access issues, and 
educational barriers to HCV treatment was also conducted. The keywords used in the search 
process included: hepatitis C, Mavyret, SVR, SVR12, treatment, efficacy, effectiveness, IVDA (IV 
drug abusers), PWID (people who inject drugs), OAT (opioid agonist therapy), methadone, 
clinic, primary care setting, costs, San Francisco, benefits, risks, burden, barriers, access, and 
comorbidities. CINAHL, PubMed, Cochrane, Scopus, and Google Scholar were the databases 
searched. A gray search of the literature was also conducted on Dynamed, UptoDate, Google, 
Medscape, and Epocrates. The search process yielded a total of 150 articles. Articles were 
selected for review if they met the inclusion criteria: current literature published between 2010 
and 2018, articles written in English, subjects being treated for HCV with antivirals, subjects 
being treated for HCV with Mavyret. The articles that were excluded were ones not written in 
English and articles that were written before 2010. While there were no scholarly articles 
available which compared the various antiretrovirals available for HCV treatment, the SFHP 
selected Mavyret as the drug of choice for two specific reasons – first, its cost compared to other 
medications is significantly lower (see Background section above), and second, patient 
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adherence tended to be higher due to fewer side effects. A total of 10 qualified articles were then 
selected for final review. The evidence was rated using the Johns Hopkins Evidence Rating tool 
(Appendix J).  
Review of the Evidence 
 The treatment options for HCV have dramatically progressed from poorly tolerated and 
moderately successful interferon-based therapies, to highly effective all-oral interferon-free drug 
regimens (Abutaleb, Kottilil, & Wilson, 2018). The available studies used for the literature 
review of Mavyret all support the fact that it is highly efficacious, and that due to its low side-
effect profile it is tolerated well and ultimately the best choice for patients who are in opioid 
agonist therapy (OAT) and treated with methadone.  
Mavyret Efficacy      
 Mavyret is the drug of choice in treating HCV patients at BAART Turk because it can 
treat any genotype of the HCV and has little to no side effects. Voelker (2018) reviews clinical 
trials, in which 2300 adult patients with HCV genotypes 1-6 showed that 92% who had received 
Mavyret for 8,12, or 16 weeks had no detectable virus in their blood work 12 weeks after 
treatment had ended (SVR12), indicating they were cured. The results of the study strongly 
support the use and effectiveness of Mavyret and suggest that this DAA should be used to treat 
all patients with HCV.  
 In a study done by Asselah, et al. (2018) called the SURVEYOR –II, after 8 weeks of 
treatment with Mavyret, there was an SVR12 produced in 98% of those infected with HCV 
genotype 2, and in 93% of the patients infected with genotypes 4,5, and 6; and after 12 weeks 
time an SVR12 was produced in 99.5% of genotype 2 patients and 99% in genotypes 4,5, and 6. 
A total of 568 patients took part in this multi-level study, two studies being open label, and 
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single-arm, and the other being a randomized, double-blind, placebo-controlled study. The 
findings of the studies suggest that the safety and efficacy of 8 and 12 weeks’ treatment with 
Mavyret is highly effective, which supports the use of this drug to treat patients living with HCV.  
 A partially randomized, open-label, multicenter, phase 3 study trial conducted by Wyles, 
et al., (2017), assessed the efficacy of Mavyret in treating patients with HCV of genotype 3, and 
had prior treatment experience and/or compensated liver cirrhosis. This specific patient 
population is traditionally difficult to treat due to limited treatment options given the complexity 
of their HCV status. A total of 131 patients participated in the study. Of the treatment 
experienced patients without cirrhosis, an SVR12 was attained by 95% of patients treated with 
Mavyret for 12 or 16 weeks. The patients who had cirrhosis and were treatment-naïve achieved 
an SVR12 of 98% at 12 weeks, and 96% of the patients with prior treatment experience attained 
an SVR12 who were treated for 16 weeks. Based on these results, this patient population 
achieved high rates of SVR12 and supports the efficacy and safety of Mavyret (Wyles, et al., 
2017).  
 The EXPEDITION-1 study by Forns, et al., (2017) is a phase three, single-arm, open-
label, multicenter study at 40 sites in Canada, Belgium, Germany, Spain, South Africa, and the 
US. All patients were over 18 years of age, had chronic HCV with genotypes 1,2,4,5, or 6, 
compensated cirrhosis, and were either treatment-naïve or were treatment exposed to interferon 
and/or ribavirin and had a failed virologic response. A total of 146 patients were in the study, and 
an SVR12 of 99% was achieved at the end of the 12-week course treatment of Mavyret, 
indicating high efficacy rate of this medication (Forns, et al., 2017).  
 In the EXPEDITION-2 study, done by Rockstroh et al., (2018), 153 patients with HCV 
and either genotypes 1-6, and HIV coinfection were treated with Mavyret. Patients with 
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compensated liver cirrhosis (16 total) were also included. Some of the patients were treatment-
naïve and others were treatment experienced with sofosbuvir, ribavirin, or interferon and 
antiretroviral naïve or on a stable antiretroviral regimen for their HIV. Treatment experienced 
genotype 3 patients were excluded. EXPEDITION-2 is a phase 3, multicenter, open-label study 
assessing the efficacy of Mavyret for 8 to 12 weeks. An SVR12 was achieved in 98% of 137 
patients who were treated for 8 weeks. The results of this study have concluded that Mavyret 
treatment for 8 weeks in non-cirrhotic and 12 weeks in cirrhotic patients is highly effective and 
well-tolerated by patients with HCV and HIV coinfection (Rockstroh, et al., 2018).  
 The study named MAGELLAN-1 by Poordad, et al. (2017) focused on 50 HCV patients 
who were of genotype 1, no cirrhosis, and had prior virologic failure to HCV direct-acting 
antivirals (DAA). It is a phase-2, open-label study with three arms. Two arms were treated with 
just Mavyret of different doses (arms A and B), and the third arm was treated with Mavyret in 
addition to ribavirin (arm C). The SVR12 was at least 95% in arms A and B, and 86% in arm C. 
Based on these values, Mavyret was highly effective and well tolerated in patients with HCV 
genotype 1 infection who had prior virologic failure with other DAA therapies (Poordad, et al., 
2017).  
 The CERTAIN-1 study done in Japan is a phase 3, open-label, multicenter study which 
assessed the safety and efficacy of Mavyret in 181 Japanese patients with HCV, genotype 1, with 
or without cirrhosis (Chayama, et al., 2017). The patients without cirrhosis were treated for 8 
weeks, and the patients with cirrhosis were treated for 12 weeks. An SVR12 was attained by 128 
of the 129 (99.2%) non-cirrhotic patients, and 52 of the 52 (100%) cirrhotic patients. The results 
of this study demonstrate a high efficacy and tolerance for Mavyret in these patients, indicating 
strong support for future patients to be treated for HCV with this drug (Chayama, et al., 2017).  
HCV OUTREACH TREATMENT PROGRAM 
 
20 
 In the SURVEYOR-I and SURVEYOR-II studies by Kwo, et al. (2017), HCV patients 
with genotypes 1-6 were treated with Mavyret for either 8 or 12 weeks. These patients had no 
cirrhosis, were treatment-naïve, or treatment exposed to interferon and ribavirin. The studies are 
open-label, multicenter, dose-ranging trials of 449 patients. For the 12-week treatment, SVR12 
was attained in 97-100% of the patients, and 97-98% was achieved in the patients with the 8-
week treatment. The results support the effectiveness of Mavyret in treating patients who have 
HCV with genotypes 1-6 and no cirrhosis as evidenced by the high rate of SVR12 (Kwo, et al., 
2017).  
 Gane, et al. (2016), conducted two studies that were open-label and phase 2. Twenty-
seven patients with chronic HCV with genotype 1, and 55 patients with genotype 3, and all had 
compensated liver cirrhosis. The majority of these patients were treatment-naïve (84%) and male 
(65%). A 12-week course of Mavyret was given to treatment-naïve patients, and a 16-week 
course was for those who had exposure to prior treatment. The overall result yielded a SVR12 of 
96-100% between both arms of the study. The only adverse effects experienced were headache, 
fatigue, and nausea. All in all, Mavyret was well tolerated by the patients in this study and is 
recommended for future use in treating HCV (Gane, et al., 2016).  
Barriers to HCV Treatment  
 An important aspect to determining successful treatment in HCV patients is to account 
for any potential barriers, especially in this high-risk population. Evaluating the barriers will help 
control the pitfalls of treatment and allow for a better exploration of the gaps perceived in 
providing care to HCV patients. The patients who have experienced barriers to access and 
treatment for HCV are typically ones that are past or present IV drug abusers. 
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 Grebely, et al. (2008) distributed surveys to 188 HCV positive illicit drug users focusing 
on the barriers associated with IV drug users. It was discovered that the major reasons for not 
seeking HCV treatment were lack of information about HCV or knowledge that treatment was 
available (23%), the absence of symptoms (20%), and the perceived side effects of treatment 
(14%) (Grebely et al., 2008). In this study, it was observed there was a low uptake of HCV 
treatment, but a high willingness to receive therapy. Based on the findings it is recommended 
that there be an increased focus on improving education about the long-term consequences of 
untreated HCV and the availability of effective treatment to expand HCV treatment among illicit 
drug users (Grebely et al., 2008).  
 A systematic review conducted by Grebely, Oser, Taylor and Dore (2013) indicated that 
HCV treatment uptake among people who inject drugs (PWID) will not increase unless the 
barriers of HCV education, screening, evaluation, and treatment are addressed. Specific barriers 
identified and addressed in this review were: systems-level (lack of screening, treatment and 
evaluation guidelines), practitioner-level (withholding treatment because of perceptions about 
poor treatment adherence, ongoing substance abuse, relapse to substance abuse, risk of 
exacerbating comorbid psychiatric disease and potential risk of reinfection), and patient-level 
(poor knowledge of HCV and the long-term consequences on health, and inaccurate perceptions 
of HCV treatment side effects) (Grebely, Oser, Taylor & Dore, 2013). The studies reviewed have 
shown that accurate guidelines to treatment initiation, monitoring and evaluation, and enhanced 
patient and provider education can increase HCV treatment uptake.  
 The evidence strongly suggests that adherence to HCV treatment in patients who are 
being treated with opioid agonist therapy (OAT) and are recently active or currently active 
people who inject drugs (PWID) can be achieved, and that this patient population can achieve an 
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SVR (Grebely et al., 2016). According to Grebely, Oser, Taylor, and Dore (2013), a history of 
IV drug use (including recent drug use) does not compromise adherence or treatment completion 
or SVR, and that occasional drug use during treatment did not affect outcomes. Directly 
observed treatment promotes the most adherence in this patient population, and this approach 
should be utilized whenever possible (Schutz et al., 2018).  
 There is strong evidence indicating that if the above listed barriers are addressed that 
treatment uptake and overall success of HCV treatment will increase and less healthcare burdens 
will be seen.  
Theoretical Framework 
The theoretical frameworks that will guide the development and implementation of this 
project are the HBM (Health Belief Model) and EBM (evidence based model). Their theoretical 
and psychological models help guide health promotion and treatment of current and future 
healthcare issues. These two theoretical frameworks will provide the support to integrate change, 
provide changes in behavior for both patients and staff, and utilize evidence as a tool to promote 
a community based treatment model.  
The Health Belief Model (HBM) was created in the 1950’s by social psychologists 
Hochbaum, Rosenstock, and Kegels (1952) to help the U.S. Public Health Service determine 
why medical screening programs that they offered were not successful (Turner, Hunt, DiBrezzo, 
& Jones, 2004). The underlying thoughts of HBM is that behavior about and towards health 
stems from personal beliefs and perceptions about a disease and the approaches used to treat the 
disease (Glanz, Rimer, & Viswanath, 2002).  
There are four perceptions that lead to the structures of the theory, which are: perceived 
susceptibility, perceived severity, perceived benefits, and perceived barriers. The HBM is based 
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on the idea that 1) people will make a health-related decision and take-action if they feel that a 
negative health condition can be avoided, like hepatitis C; 2) the person has an optimistic thought 
and expectation that by using such endorsed health action the person will be prevented from 
experiencing a situation that negatively affects their health; and 3) the person feels confident and 
comfortable enough to carry out the health action (Glanz & Rimer, 1997). Being able to 
understand the factors that affect behavior compliance can help healthcare providers influence 
positive health outcomes for the patients receiving care. The HBM will guide the project at 
BAART Turk to identify the perceived threats and barriers that patients may have and possibly 
encounter during treatment, and understand how to avoid these hindrances to promote that best 
patient and overall project result outcomes.  
Sackett (2014) defines EBM as the “conscientious, explicit, and judicious use of current 
best evidence in making decisions about the care of individual patients”. The EMB was created 
to develop and promote an “explicit and rational process for clinical decision making that 
deemphasized intuition and unsystematic clinical expertise while emphasizing the importance of 
incorporating the best research findings into clinical care” (Satterfield, et al., 2009). Creating 
individualized treatment regimens for diseases, like HCV, using this model will provide the 
patient the utmost effective and safe care. The foundation of the EBM model will guide 
providers to create individualized approaches for each patient to promote the most successful and 
effective response to the treatment regimen, including adherence to the medication regimen and 
time-sensitive therapeutic lab draws.  
Ethical Considerations 
HIPAA considerations required that all patient information was to be accessed through 
the online portals that were only accessible at BAART Turk. No patient names or identifiers 
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were used throughout this paper or in other documents that were seen and used outside of the 
HCV treatment program at BAART. IRB approval was not indicated for this project since it did 
not qualify as research. However, an SOD was completed because the project qualified as a 
practice change model. 
Of the six values that are known as the principles of the Jesuits, ‘women & men for and 
with others’ (Creighton University, 2018) is reflected in this project. The focus of the project 
exhibits the value of providing community outreach and enhancing care for the poor and 
marginalized groups by encouraging ‘care for the individual person’ (Creighton University, 
2018). As discussed earlier in the theoretical framework of the EBM, an individualized approach 
to patient care can promote adherence to and overall success in patient health outcomes.  
The seventh provision of the ANA Code of Ethics is demonstrated in this project, which 
states “the nurse, in all roles and settings, advances the profession through research and scholarly 
inquiry, professional standards development, and the generation of both nursing and health 
policy” (American Nurses Association, 2015). Research and scholarly inquiry has allowed the 
DNP author to identify the need for a HCV treatment program for the high-risk patient 
population seen at BAART Turk, and has helped initiate a HCV treatment policy for the patients 
in the BAART Turk setting.  
SECTION III: Methods 
Specific Aims 
 The overall goal of the project is the reduction of HCV infection among positive patient 
population in SF at one community-based clinic as a model for a larger scale community-based 
treatment protocol across all BAART clinics. The specific target population was patients at 
BAART Turk who were living with active HCV and were mostly PWID. The implementation of 
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a HCV treatment program at BAART Turk was important because many of the patients that are 
seen there are high-risk for HCV, and screening, diagnosing, and treating are effective in this 
specific patient population.  
 The aim of the project was to have at least 80% of the identified hepatitis C virus (HCV) 
positive patients at BAART Turk Clinic enrolled and successfully complete treatment with the 
antiviral medication Mavyret by December 2019. Appropriate measures to document success 
were based on patient participation, toleration and use of Mavyret and SVR at 12 weeks.  
Objectives  
The primary objectives of this project were: a) to decrease rates of HCV infection using 
effective drug therapy, b) educate the patient population who was at high-risk for infection, and 
c) to prevent reinfection through education. According to Manns et al. (2017), as long as there is 
no availability of prophylactic vaccines for HCV, the treatment and control of the virus must be 
through prevention strategies (ie: sterile medical equipment in developing countries, no re-use of 
needles while using drugs), effective screening programs, and access to treatment for all. This 
project will use the following goals to guide successful implementation. 
a) To educate 100% of the providers at BAART Turk on HCV and increase knowledge of 
HCV infection, including screening, assessment and treatment protocols by completing a 
post seminar survey with improved scores compared to the pre-education survey.  
b) To design and implement an 8-week HCV treatment program utilizing the medication 
Mavyret for BAART Turk patients.  
c) To achieve 100% uptake and success of the HCV treatment program at BAART Turk 
by all eligible HCV positive patients, as demonstrated by an attained SVR at 12 weeks.  
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d) To achieve 85% staff satisfaction with the implementation of the project at BAART 
Turk. 
e) To achieve an overall 85% patient satisfaction with project effectiveness and 
implementation. 
The collaboration and development of a HCV treatment program at BAART Turk Clinic 
was designed to create a low barrier, easy to treat workflow with San Francisco Health Plan 
(SFHP) that allowed easy approval and execution of treatment options for patients at BAART 
Turk Clinic. 
Interventions 
Developmental Phase  
During the developmental phase of the project, focus was given on using the gathered 
data and evidence to create the educational materials for staff, providers, and patients. A 
PowerPoint was created by the DNP author for the counselors at this clinic to educate on what 
HCV is, the importance of HCV being treated, and how they as counselors could help support 
their clients in receiving care and being treated and cured from HCV. Along with the 
PowerPoint, educational pamphlets and flyers about HCV created by End Hep C SF were used as 
reference for the counselors.  
The second phase of development involved creating the clinic algorithm for treatment 
(Appendix N). This included working with the medical director, lead physician, the lead NP, and 
the DNP author in designing a process for screening at risk patients, deeming them eligible, and 
recruiting them into a cohort model for treatment. The cohort design was selected, to ensure a 
more streamlined process of tracking and monitoring the patients as an introductory model.   
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The selection and preparation of the first cohort involved completing chart reviews to 
determine the eligibility of patients. The eligibility criteria were: the patient had to have active 
insurance through the SFHP, the patient could not be co-infected with active hepatitis B or HIV, 
the patient had to have confirmed HCV based on blood test results, and have no evidence of a 
compromised liver (liver cirrhosis). A total of several hundred chart reviews were done, and by 
way of using mail, phone calls and clinic visits six patients were recruited into the first cohort. It 
was important to conduct chart reviews to see which patients did and did not have an assigned 
primary care provider (PCP), which patients were due for a HCV screening, and which patients 
were active with BAART Turk, but have not seen a PCP for a considerable amount of time (one 
year or over) and were discovered to be HCV positive the last time they were seen. These 
patients were sent letters in the mail to help initiate the process of receiving HCV education and 
treatment. In order to efficiently follow all of this information, an excel spreadsheet was created 
to keep track of these patients. 
A relationship between USBioServices and the clinic was established since the clinic was 
receiving the medication Mavyret from this pharmaceutical distributor. A conference call 
establishing a profile for the medical director, staff nurse practitioner, lead nurse, staff physician, 
and DNP author of the clinic was done so medications could be ordered for the HCV patients.  
The DNP author met with the dean of the college of nursing of the University of San 
Francisco (USF) to propose the project idea and the goals and objectives, and to create a 
timeline. 
Educational Phase 
The educational sessions were the next step in the process.  The DNP student led the 
educational sessions to the counselors, staff, and providers via PowerPoint presentation at the 
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site over a 1-hour period during their lunch break. Snacks and 25 print-outs of the PowerPoint 
slides (each packet being 10 pages) were printed for a total of 25 attendees. Immediately 
following the educational session, the knowledge attained and the teaching effectiveness of the 
DNP author was assessed by administering pre- and post-education surveys distributed to the 
counselors who would be working directly with the patients. Following the staff education phase, 
education was provided to the patients who were infected with HCV via the lead NP, lead 
physician, and medical director during medical appointments. Patient education about HCV was 
provided verbally during individual clinic visits (and reinforced at subsequent clinic visits) by 
the provider and by distribution of handouts given to the patient directly from the provider. The 
main points addressed were side effects of the medication and the importance of treatment 
adherence.  
Implementation Phase 
The algorithm created for the HCV treatment program (Appendix N) at BAART Turk 
helped identify patients that were qualified to receive HCV treatment. Patients were selected for 
blood lab work-up of HCV by determining if they were high-risk (IVDA, homeless, history of 
other forms of substance abuse). After this was done, the identified patients were notified via in-
person appointments with one of the providers involved with the project that they were 
categorized as being high-risk for HCV, and that blood work was ordered to test for the presence 
of HCV. If the blood work came back as the patient being HCV positive the patient was made 
aware of their positive HCV status during a follow-up blood work appointment with the 
provider, and provided a pamphlet and verbally educated about what HCV is, notified that they 
qualify for a HCV treatment program being established at the clinic. The provider then assessed 
the patients interest in receiving treatment. If the patient agreed to treatment, further education 
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was provided about next steps including: blood work that needs to be obtained during and after 
treatment, the type of medication (Mavyret) they will be receiving and potential side effects 
associated with said medicine, DOT vs take-home therapy, frequency of taking the medicine, 
future check-ins with the provider, and other resources and references regarding HCV. After the 
patient received education about HCV and expressed interest in receiving treatment, a written 
consent was signed by the patient and kept in their patient profile chart at the clinic. The DNP 
author took into consideration all the information that was obtained from the patients, 
counselors, and staff at the clinic to establish the most effective, efficient, and clinically and 
financially feasible HCV treatment program possible. 
To ensure the safety of patients, the patient’s liver panel had to show no signs of a 
decompensated or compromised liver to qualify for treatment at BAART Turk. If the blood work 
showed signs of an inadequate liver function the patient was referred to the liver clinic at 
University of California San Francisco (UCSF) for further evaluation. If the patient was cleared 
to receive HCV treatment based on the results of the work-up done at USCF, their treatment was 
initiated and managed by UCSF so that closer monitoring of the patient’s liver enzymes could be 
done.  
Initially 20 patients were identified as being high-risk for HCV and were ordered to have 
blood work done. After the blood work was reviewed, a total of six patients qualified for and 
were recruited for HCV treatment. It was decided that a cohort model be followed to proceed 
with treatment of the identified patients for the ease of monitoring by providers. Consents to 
receiving treatment and obtaining blood work at 4-weeks into treatment (liver panel, viral load), 
8-weeks at treatment completion (liver panel, viral load, SVR), and 12-weeks after treatment 
completion to screen for SVR were signed by each of the six patients in the cohort. The lead NP 
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was responsible for the review and monitoring of blood work throughout the course of each 
patient’s treatment.  
 Each of the six patients in the cohort had six visits during their HCV treatment. The first 
visit consisted of the provider performing an in-person evaluation and ordering blood work to be 
done. The labs ordered were: complete blood count with differential (CBC with diff), complete 
metabolic panel (CMP), PT/INR, Hep C viral RNA genotype, Hep A antibody, total Hep B core 
antibody, total Hep B surface antigen with reflex, Hep B surface antibody, and HIV fourth 
generation. After the labs were processed and confirmed that the patient was HCV positive, the 
provider reviewed the labs with the patient and educated them about HCV, consequences if left 
untreated, and that there is a HCV treatment program now being offered at BAART Turk that is 
free of charge to them. Other topics discussed were possible side effects of the medication 
Mavyret and the importance of treatment adherence. Gaining patient consent to participate in the 
program was the final step of the initial visit.  
 The next visit was one week after the initial evaluation to start the medication. The first 
dose was directly distributed from the provider to the patient, and for the remainder of their 
treatment the patient was to receive their daily dose of medication from the dispensing nurse via 
DOT. A follow-up appointment one week after the first week of administration of the medication 
was scheduled with the provider to assess for medication side effects and treatment adherence. 
At four weeks into treatment blood work was done which consisted of: CMP, a HCV viral load 
(HCV VL), and a core antibody HBC viral DNA if the patient was HBV positive upon 
evaluation. At eight weeks, a HCV VL was drawn, and then 12-weeks after treatment completion 
a SVR 12 was drawn to determine a cure from HCV.  
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Table 2  
 
Visit Number and Content of Each Visit  
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The DNP author kept track of the patients receiving HCV treatment using an Excel 
spreadsheet. The course of Mavyret was either 8 or 12 weeks (depending on the grade of liver 
cirrhosis of the patient), and blood work to detect the presence of a viral load was drawn at 4, 8, 
and 12 weeks, and again 12 weeks after treatment completion to see if they had attained a 
sustained virologic response, also called an SVR12. The lab values during and after treatment 
helped the clinic determine the effectiveness of the establishment of the HCV treatment program 
and what was working well and what changes needed to be made.  




A Gantt chart was created to provide a schedule to help plan, coordinate, assign, and 
track specific tasks required for the project (Appendix I). The Gantt outlines the development, 
implementation, and evaluation timeline for the project. The project spanned 10 months. 
Initiation of the project began with meeting with the stakeholders of the project, and then 
acquiring knowledge about the topic of the project (HCV) through online modules, connecting 
and meeting with expert panels on HCV, and having lectures with the staff MD of the clinic. 
After this part was completed, a teaching was provided by the DNP author to the counselors 
about HVC. During the time of the counselor teaching, the DNP author and the stakeholders 
established a relationship with USBioServices to set up a profile for ordering the Mavyret. The 
roll out date of the project was in September 2018. Blood work of the patients was obtained prior 
to the start of treatment, during treatment at 4 and 8 weeks, and then 12 weeks after the 
completion of treatment. Data collection via the use of Excel and Practice Fusion at the clinic 
were utilized to organize findings and results.  
SWOT Analysis  
A Strengths, Weaknesses, Opportunities, Threats (SWOT) analysis was performed to 
identify what could impact the forward progression of the HCV treatment program at the clinic 
(Appendix F). It allowed the DNP author to focus on the strengths of the project to minimize 
threats and to use opportunities to the best advantage.  
One of the major strengths of the project was its ability to address the healthcare gap seen 
in San Francisco regarding the lack of access for high risk patients to receiving HCV treatment 
and cure from disease in their primary care setting. Other proposed strengths were: the use of 
medication that was proven to have little to no side effects (so it was easily tolerated by patients), 
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the distribution of the HCV medications via DOT (which promoted patient adherence to the 
medication regimen), and frequent contact between the lead NP, lead physician, and medical 
director with the patients during primary care appointments and when the patient came in for 
their DOT. Another strength of the project is the grant that was awarded to BAART Turk from 
the SFHP to create and implement a HCV treatment program. The establishment of the program 
promoted and provided low barrier access to HCV treatment among high-risk, hard to reach 
patient populations (IV drug users, homeless). Another strength lies in the reduction of 
transmission of HCV among high-risk patient populations.  
The key weakness identified in this project was determining how to improve access to 
receiving HCV treatment. Other weaknesses were related to factors associated with patient 
compliance: obtaining timely and protocol driven blood work from patients to determine the 
status of their HCV and if any liver cirrhosis was present, the possibility of missing follow-up 
visits with PCP due to lack of transportation which created a lack of adherence to the medication 
regimen. The patient demographics (they were homeless and did not have an address or phone 
number to get into contact with) also created a barrier to medication adherence. Lastly, there 
were no patient incentives in the budget to encourage the patients to have their blood work 
drawn, attend follow-up appointments, or continue with the medication regimen, apart from the 
proposed idea of HCV cure.  
  The major opportunity that was presented by this project was the community outreach to 
HCV patients who had few treatment options toward a cure of HCV infection. Other 
opportunities were: the rate of HCV and the comorbidities associated with it would bring 
healthcare costs in San Francisco down, awareness of prevention and reinfection prevention 
methods were taught to the community, and chronic HCV initiatives were established at the 
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clinic. These opportunities create another place in the community where HCV patients can be 
treated, in turn improving access for this patient population.  
The threats identified were: homeless patients were unable to be tracked/contacted, 
unable to identify all potentially qualifying patients due to discrepancies within the charting 
system, the medication shipment from USBioServices did not come in time or there was an issue 
with the delivery, the patient dropped out of being treated for HCV due to side effects or 
personal reasons, the patient moved away, the patient expired, the patient was no longer a 
methadone patient and did not want to come back to this clinic, and quality improvement 
projects were being rolled out at the time of the project which posed as a barrier to progressing 
forward.  
Time and Cost Summary 
The direct costs (Appendix G) were split into three categories which were ‘staffing’, 
‘training’, and ‘travel’, and were based off a 52-week (one year) budget. The budget calculated 
for ‘staffing’ was based on the salaries and time of the DNP author, the project oversite (a 
physician), and the consulting public health physician. The budget calculated for ‘training’ 
consisted of the salary and time of the counselors, the site nurse practitioner support, and the 
supplies and resources used for the counselor training (printing of PowerPoint slides, pens, and 
refreshments). The budget calculated for ‘travel’ included mileage based off the IRS standard 
mileage rate (IRS, 2017), bridge tolls, and parking. The overall cost to implement this project at 
BAART Turk for six patients totaled $106, 473.27, which was covered by the grant from SFHP. 
The medication Mavyret was covered by the grant distributed by SFHP to initiate the HCV 
treatment program at BAART Turk, so this was not calculated into direct expenses. 
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 According to End Hep C SF (2017), there are a total of 12,000 people in SF living with 
active HCV, and the median ages at death for people living with active HCV is 60 years, 
respectively (Carter, 2014). Based on an analysis done by Razavi et al. (2013), the total lifetime 
healthcare costs of individuals in the U.S. with advanced liver disease due to HCV is $6.5 billion 
per year, and the lifetime cost of an individual living with HCV is estimated to be $64,490 
annually. The calculated ROI is 27.2 indicating that the project, through treatment with Mavyret, 
reduces the cost of successful treatment to 27.2% of the average cost of treatment over a 
patient’s lifetime. This supports the premise that HCV treatment in the SF patient population will 
greatly decrease healthcare costs associated with this disease, and overall positively benefit the 
healthcare system.  
Grant/Projected Costs 
Through the SFHP the BAART Turk HCV Grant, a total of $60,000 will be funded 
annually to the clinic over a total of three years (September 2017 to September 2020) to cover 
staffing ($53,000), equipment ($2,000), and other anticipated costs ($5,000), which will 
accumulate to a total of $180,000 by September 2020. The clinic’s target was to start out by 
treating 20 patients in the first cohort, and then eventually treat hundreds of high-risk patients by 
September 2018.  
Approximately 20,000 patients die each year from HCV-related liver disease, which in 
2013 surpassed the total number of deaths from 60 other diseases reported to the CDC. Some of 
these diseases include, tuberculosis, HIV, and pneumococcal disease (Alkhouri, Lawitz & 
Poordad (2017). According to Dartmouth Medical School (2018), more than 80% of HCV 
patients will develop chronic liver disease, 15-20% will develop cirrhosis in a 5-year period, and 
25% may have cirrhosis by 10-20 years. Hepatitis C is responsible for one-third of all liver 
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transplants, and the cost of liver transplants for HCV alone costs the US healthcare system nearly 
$300 million annually. The average lifetime costs of HCV without liver transplant costs about 
$100,000 for each patient yearly. If 80% of the 4.5 million actively infected HCV patients 
develop chronic liver disease, the total lifetime cost for this group is around $360 billion dollars. 
And if the estimated survival of these patients is 40 years, the annual healthcare cost for the US 
population with chronic HCV is estimated to be as high as 9 million dollars (Dartmouth Medical 
School, 2018). With these staggering numbers, it is apparent that the US has a serious issue it 
needs to face when it comes to treating this patient population to lower healthcare costs 
(Appendix G). According to Alkhouri, Lawitz & Poordad (2017), recently approved regimens 
have helped close gaps in access to healthcare, and almost all HCV-infected patients can be 
cured. Future research is needed to develop a preventive vaccine, eliminate the risk of vertical 
transmission from mother-to-child, and to decrease the number of acute HCV infection cases.  
Work Breakdown Structure/Stakeholders 
 A work breakdown structure was created by the DNP author (Appendix D) to provide an 
outline of the key deliverables of the project that were to be executed by the project team. The 
ultimate focus was to establish a HCV treatment program at BAART Turk Clinic. The first phase 
was to establish a relationship with the stakeholders, who were the medical director of BAART 
Turk, the lead physician, the lead NP, and the counselors of the patients. Phase two was for the 
DNP author and the lead NP at BAART to attain knowledge of HCV and meet with the 
appropriate HCV experts. Next was to provide an education training session to the counselors of 
the patients. Phase three consisted of developing a plan to move forward with the 
implementation of the project. Phase four was the actual carrying out and launching of the 
project.  




  A communication flow chart addressed the type of information that was communicated, 
who it was communicated to and with, how often it was communicated, and the method of 
communication that was used (Appendix H). The communication happened between the DNP 
chair, DNP committee, and the on-site staff NP, MD, and the medical director via email, in-
person, and phone. Important matters were discussed were: project coordination and planning, 
the status of the project, changes in the project methods, reports of milestones, and variances. It 
was important to know what communication paths to follow to promote efficient and effective 
communication which allowed more organization.  
Study of the Interventions 
The DNP author analyzed the results of the three identified measures (see Section III: 
Objectives, page 23) in various ways. The knowledge of the counselors was assessed by 
comparing the in-person pre- and post-test survey results. The test consisted of a total of nine 
multiple choice questions (Appendix E). The same test was distributed before and after the 
teaching. The successful implementation of the protocol was assessed by the number of patients 
who were recruited and started treatment. Next, the number of patients who completed treatment 
were evaluated, which was all six patients who were recruited and started. Along with treatment 
completion, attained SVR was also evaluated through blood work. All six of the patients attained 
SVR indicating a cure from HCV. 
Staff satisfaction of project implementation was evaluated through a personal survey and 
reflection of the project. Staff satisfaction surveys were created by the DNP author on 
SurveyMonkey and distributed to the five staff directly involved with the program via email. All 
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five of the staff completed the survey. There was a total of three questions on a Lichert scale that 
produced qualitative data (Appendix J).  
After the completion of treatment, in-person patient satisfaction surveys were 
administered to the six patients who completed treatment during their provider follow-up visits. 
The survey consisted of a total of six questions including important topics, like medication side 
effects and if they would recommend the program to future patients. Five of the questions were 
on a Lichert scale that produced qualitative data, and one questions was ‘yes’ or ‘no’ (Appendix 
K). 
Measures 
The five identified outcome measures for this project were: 
1. 90% of the participating providers at BAART will increase their knowledge related 
to HCV screening, assessment, treatment as evidenced by pre- and post-test surveys 
indicating scores of 90% and above. There will be a total of 9 questions asked and 
will demonstrate knowledge about HCV treatment protocols and side effects. 
2. Ten BAART patients will be identified, screened, assessed, and started on HCV 
treatment with Mavyret based on the identified and initiated HCV treatment protocol 
at BAART Turk.  
3. At least 50% of selected patients who received treatment for HCV will complete 
their medication course of Mavyret and have an attained SVR12. 
4. 85% of the providers will express satisfaction with the design and implementation of 
the HCV treatment program. 
5. 85% of the patients treated will express satisfaction with the overall effectiveness 
and implementation of the treatment program.  






With regard to provider education the targeted outcome was that 90% of participating 
providers would increase their knowledge related to HCV screening, assessment and treatment. 
Actual results demonstrated that 100% of providers increased their knowledge as defined above. 
I believe this is attributable to effective teaching methods, provider enthusiasm for the program, 
and 100% provider participation in the educational session.  
With regard to the design and implementation of the HCV treatment program, the 
original target was to identify and serve 10 BAART Turk patients with Mavyret. Actual results 
included treatment of only six HCV positive patients, all of whom successfully completed the 
HCV treatment program and demonstrated attained SVR12. Fewer patients were eligible for 
treatment due to the presence of compromised liver function in otherwise eligible patients.  
With regard to completion of treatment, the targeted outcome was 50% of selected 
patients would successfully complete treatment and demonstrate attained SVR12. Actual results 
demonstrated a 100% completion rate of all patients selected and enrolled in the program., and 
an attained SVR12. Success was attributed to frequent provider contact and low side effect 
profile of the medication.  
With regard to the rate of provider satisfaction with the design and implementation of the 
program, the target was 85%. Actual results demonstrated 98% rate of satisfaction. The high 
satisfaction rate was attributed to the efficiency of the program design and delivery, and 
coverage of costs by funding from the grant.  
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With regard to patient satisfaction with program effectiveness and implementation, the 
original target was 85%. Actual results demonstrated 98% patient satisfaction rate, attributable to 
frequent provider contact and a strong patient support network within the healthcare setting.  
Throughout this project, data was collected, organized, and analyzed in an Excel 
spreadsheet and analyzed using Excel tools, including bar graphs, yields, and descriptive analysis 
that was accessible to the DNP author and the appropriate stakeholders. Each intervention was 
analyzed and assessed using one or several of the above identified methods. Both qualitative and 
quantitative data were collected.  
Evaluation  
 The cohort consisted of a total of six patients who were enrolled in and completed 
treatment in the HCV treatment program. A total of four staff were directly involved with the 
implementation of the program, which included the lead nurse, medical director of BAART 
Turk, lead physician, and lead NP.  
 Only the results of patients who had completed the entire course of treatment of Mavyret, 
and had completed all the required blood work before, during, and after treatment were assessed 
and analyzed. An SVR12 was attained by all patients diagnosed with HCV 12-weeks after 
treatment completion of Mavyret. A successful treatment outcome was an SVR12 where the 
HCV was undetectable for 12-weeks after the completion of treatment, indicating a cure from 
HCV (Porter, 2015). 
The DNP author evaluated the results of the five identified objectives in various ways. 
With regard to provider education, materials that included in-person presentations, distribution of 
pamphlets and other printed education materials were provided. Provider knowledge was 
assessed by the creation and distribution of a printed post-teaching survey by the project leader. 
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Based on the results of the survey after they were physically collected and analyzed by the DNP 
author, the provider teaching was 100% effective.  
In regard to the design and implementation of the HCV treatment program, there was 
completion of an electronic and printed algorithm that presented the layout and workflow of the 
HCV treatment program at BAART Turk. After several revisions of the work flow program 
structure, a final revision was achieved and was 100% effective in guiding providers through the 
HCV treatment program initiation, monitoring and evaluation of the identified HCV patients. 
This was evidenced by the unobstructed flow of patient progression through the program from 
start of taking the medication to ending with obtaining the SVR12, 12 weeks after treatment 
completion.  
With regard to completion treatment, data was collected and analyzed based on the 
completion rates of the patients at BAART Turk who were treated for HCV. Once a patient had 
completed their HCV treatment regimen and had their blood drawn to determine the presence of 
an SVR 12, 12 weeks after treatment completion, it was determined that the HCV treatment 
program was successful and that the patient was cured from HCV. Out of the six patients who 
qualified for the HCV treatment program at BAART Turk, all six completed treatment, resulting 
in 100% efficacy and effectiveness of the program.  
With regard to provider satisfaction, data from the obtained surveys showed that there 
was a high satisfaction rate based on the 98% achieved rate. The DNP author believes this is 
primarily attributable to the funding from the grant, and shows that grants are an efficient and 
effective way to initiate programs at clinics.  
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With regard to patient satisfaction, data from the obtained surveys showed there was a 
high satisfaction rate of 98%. The DNP author believes this is attributable to the frequent 
provider contact.  
SECTION IV: Results  
Overall, the implementation of the HCV treatment protocol at BAART Turk proved to be 
highly successful. Of the desired 20 enrolled patients, 6 were enrolled, remained compliant, and 
completed treatment with an attained SVR at 12 weeks.  Staff and providers expressed a positive 
attitude towards the knowledge gained, and felt that the protocol was feasible and well driven.  
Provider Knowledge 
 A total of 25 counselors were at the counselor training session conducted by the DNP 
author. The same pre- and post-test survey were distributed in-person to the counselors before 
and after the training to assess their knowledge on the topic of HCV. Survey results were directly 
collected in-person and analyzed by the DNP author. There was a score of 80% understanding of 
HCV before the teaching and a score of 100% after the teaching.  
Patient Satisfaction  
A total of six patients started and completed treatment and attained an SVR12. Based on 
the results of the anonymous patient satisfaction survey there was an overall very high patient 
satisfaction rate (99%). With the exception of one patient who scored a ‘4/5’ regarding the 
survey question ‘how satisfied were you with the medication itself?’, to which he/she answered 
that patients need to be informed of the potential weight gain from the medication, the other 
survey questions scored by this patient, and all the other patients, registered a score of ‘5/5’ on a 
total of six questions.  
Staff Satisfaction 
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The results of the ‘BAART staff satisfaction survey’ (Appendix J), which was created 
and distributed by the DNP author through a SurveyMonkey, reflected a high staff satisfaction 
rate (98%). A total of five staff who were directly involved with the HCV treatment program 
consisted of three medication dispensing nurses and two providers. The total involved staff 
completed the survey. The survey consisted of a total of three questions, and all who took the 
survey rated their experience with the HCV treatment program as ‘highly likely’ or ‘likely’ that 
the HCV treatment program is sustainable, and that the program contributed to overall 
improvement of HCV patient outcomes. The last survey question was an open-ended answer that 
asked about any improvements and/or changes that could be made to the current HCV treatment 
program model at BAART that could make it better.  One individual skipped the question and 
did not answer, but the other 4 answered. One response was to have someone from quality 
improvement focus on the project. Another was for BAART to be provided resources to enhance 
patient compliance with check-ups and provider visits (ie: a gift card incentive, bus or taxi 
voucher for transport to the outpatient liver clinic). One individual stated it would be appreciated 
if the providers clearly explain to the patients that they need to take all 3 pills of the HCV 
antiviral Mavyret at the time of dosing in front of the dispensing nurse. Apparently, patients were 
under the impression that they could take the Mavyret home with them and dose it themselves. 
The final shared thought was the dispensing staff would appreciate to be updated of the treatment 
results of patients (ie: attained SVR12) since they have no way of knowing if the treatment was 
successful or not, and if the patient is cured from HCV. All the responses are valid and provide 
excellent feedback on how the HCV treatment program can be improved from the medical 
provider standpoint.  
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The results of the patient and staff satisfaction surveys are indicative and supportive of 
the fact that HCV treatment is sustainable and feasible in the PWID population, and that other 
clinics interested in establishing and implementing a HCV treatment program into their setting 
should be encouraged and confident in doing so.  
HCV Cure Rate 
 Of the six patients who started and finished their HCV treatment, six completed treatment 
and 100% achieved SVR, indicating a cure from HCV.  
Barriers to Implementation 
There were many barriers that were encountered in this project. The first was screening 
and identification of patients which were discovered during patient chart reviews. It was 
discovered that the monthly generated patient list from SFHP were not accurate, which prevented 
the clinic from determining who was an active patient and might qualify for treatment versus 
someone who was inactive, assigned to a different clinic, or had established themselves at a 
different clinic and therefore was disqualified from treatment at this clinic.  
There were some patients who were assigned to Anthem Blue Cross and Medi-Cal, and 
these do not generate monthly lists, so it was challenging to determine if patients were active 
with their insurance and receiving healthcare or not. In this same group, some patients were 
unaware that they were assigned to this clinic and ended up establishing their care at a different 
clinic. It took a substantial amount of time to figure this out after spending a lot of time and 
effort investigating and tracking down patients and where they were receiving care.  
Another issue was the clinic was rolling out a quality improvement (QI) program that 
interfered with the progression of the project. The time and resources that were being used 
towards the HCV treatment program were put to a halt until the QI project was completed.  
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While multiple stakeholders were working as a collaborative team and conducting patient 
chart reviews, it was very important to create a key/legend to avoid confusion. This is not done 
originally, so work that had already been done was done again, and in turn this created 
inefficiency and loss of progression of the project.  
The second issue was patients were not motivated to initiate or adhere to their treatment 
regimen. This included: not coming to follow-up appointments, not having time-sensitive blood 
drawn at Quest Diagnostics or at the clinic, not adhering to the medication regimen via DOT 
(direct observational therapy) or take-home, and/or the patient was a past methadone patient and 
did not want to return to this clinic for personal reasons. The budget for the HCV treatment 
program did not include incentives for the patients, like gift cards to Target, Safeway, or CVS, 
which would have tremendously helped with adherence to the HCV treatment. Patient incentives 
would have been very helpful since previous clinics who have established HCV treatment 
programs had incentives in their budget and said it was highly effective.  
It was challenging to determine if the patient had, had labs drawn or not, and which lab 
values were the most recent. For example, the San Francisco Department of Public Health 
(SFDPH) and the patient care system used at the clinic were on different databases and did not 
share information. The patient occasionally had HCV labs drawn at a hospital, but since the two 
systems between SFDPH and the clinic did not communicate, it was impossible to determine 
when and if labs were drawn, and it would take time and effort to have access to these records 
(obtaining a release of information (ROI) from the hospital).  
Another issue was the medication shipment would occasionally arrive late or the 
shipment would not come at all. Two-weeks’ worth of Mavyret was sent in each shipment for 
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each patient. It was learned to avoid failure of mediation delivery and receipt by making sure the 
request for the medication was put in as early as possible.  
Wirfs (2018) states the hepatitis B virus (HBV) could become reactivated during or after 
treatment with Mavyret. It was important to test all patients for HBV infection by measuring the 
HBsAg and anti-HBc prior to initiating therapy with Mavyret (Wirfs, 2018). After this was 
checked, it was wise and beneficial for the patient to receive both an HAV and HBV vaccine. 
Unfortunately, pharmacies like CVS and Walgreens, do not carry either vaccine unless ordered 
specifically for a patient. The DPH grant at the clinic covered only HAV vaccine, not HBV. This 
was another barrier that interfered with treatment adherence.  
Lack of insurance to cover Mavyret, which in turn limited patient access to receiving and 
adhering to the treatment regimen, interfered with treatment progression. For example, Medicare 
did not cover Mavyret, it only covered Harvoni. Other factors that limited patient access were the 
patient did not have a car, did not have money for bus fare, lived too far to walk to appointments, 
or other issues that impeded their access, such as being homeless.  
Limitations 
The limitations identified include some patients being ineligible for initiation of HCV 
treatment at BAART due to the status of their liver function; shipments of the HCV medication 
would sometimes not be delivered on time resulting in failure of dosing the patient on the desired 
day and time; patients did not have access to transportation to attend appointments for dosing of 
the HCV medication, to follow-up with the provider, have labs drawn, which overall resulted in 
delay of treatment; and there were times when the patient was not able to make it to BAART 
Turk during their open hours to have labs drawn, so they would have to go to a different clinic 
that was less convenient to travel to.  
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Based on the identified limitations discovered during the creation, implementation, 
results and findings of this project, it is recommended that patient incentives (i.e., gift cards, taxi 
vouchers, bus passes) to enhance and encourage treatment adherence (i.e., to have labs drawn, 
dosing of HCV medication) be included in the project budget, and that a back-up supply of the 
HCV medication be available in case a delivery does not come on time. In the absence of an 
existing HCV treatment protocol, the project HCV treatment guidelines were created at BAART 
Turk, and they excluded patients who had poor liver function. Hopefully as HCV treatment 
advances, future patients who do have decompensated liver function will be eligible for the 
immediate initiation of HCV treatment at BAART.  
SECTION V: Discussion 
Summary 
Of the key findings in this project, the major one identified was the fact that high-risk 
patients, particularly ones who are PWID, can be effectively treated and cured of HCV. The 
number of PWID who are assessed and treated for HCV is increasing and it is important that 
access be provided for this patient population because maximizing treatment for PWID can be an 
effective preventative measure for decreasing transmission and mortality associated with long 
term consequences of HCV. Reflecting back on the available literary evidence and positive 
outcomes of the project, it is evident that high-risk patient populations (PWID) who have HCV 
can be effectively treated and cured of HCV, and that this patient group should not be excluded 
from receiving treatment. The knowledge of the identified HCV positive patients was assessed 
by verbal confirmation that they understood there was access to and availability of HCV 
treatment at the clinic. 
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Along with the 100% treatment adherence and the one patient who revealed in their 
patient satisfaction survey that they had the undesirable side effect of weight gain, the majority 
of the patients were highly satisfied with the treatment program and their personal experiences, 
despite some of the challenges, such as lack of transportation and incentives and inconvenient 
clinic hours. The project effectively demonstrated that HCV treatment for high-risk patient 
populations can be truly successful and allow them to achieve cure as defined by attained SVR, 
and additionally, this project overcame many of the previously identified obstacles to successful 
HCV treatment, including difficulty with treatment adherence due to lack of patient education 
and knowledge, significant side effects, and lack of access to HCV treatment programs in 
geographic areas prone to high risk of infection.  
Based on the results and findings of the patient and staff survey results, and the 100% 
outcome of completion of HCV treatment and attained SVR, it can be confidently recommended 
that the creation and implementation of HCV treatment programs in clinics that are primary care 
homes for high-risk patient populations is highly feasible, efficacious and can be successful.  
Conclusion 
It is widely known that there is a lack of access to and availability of HCV treatment for 
high-risk populations in the San Francisco community. The implementation of the HCV 
treatment program at this clinic will continue to be very beneficial by reducing healthcare costs 
associated with HCV and its comorbidities in San Francisco. The program can also serve as a 
model for other clinics in the Bay Area for effective treatment of HCV. The project demonstrates 
the successful establishment of a HCV treatment protocol that is sustainable, progressive, and is 
clearly efficacious in the care and treatment of HCV in this high-risk population, leading to a 
decreased burden to society and overall healthcare expenditures.  
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SECTION VI: Other Information 
Funding 
Besides the BAART Turk HCV Grant funding supplied by the SFHP, there was no other 
identified need for outside funding for this project. The DNP author did not receive any 
compensation for time spent traveling, planning, implementing, or evaluating the project. There 
were some minor out of pocket costs absorbed by the DNP author, which are reflected in the 
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SECTION VIII: Appendices 
 
Appendix A: Statement of Non-Research Determination Form 
 
DNP Statement of Non-Research Determination Form 
Student Name:__Annie Pedlar___________________                                                                                                                
Title of Project: HCV Treatment Program at BAART Turk Clinic 
Brief Description of Project: Establishing and implementing a HCV treatment program 
at BAART Turk Clinic in San Francisco, CA.  
A) Aim Statement: The overall goal is to screen, assess, and treat HCV positive 
patients at BAART, to decrease rates of HCV infection using effective drug 
therapy, educating the patient population who is at high-risk for infection, and 
preventing reinfection through education. 
Objective 1: To educate 100% of the providers at BAART Turk on HCV and 
increase knowledge of HCV infection, including screening, assessment and 
treatment protocols by completing a post seminar survey with improved scores 
compared to the pre-education survey.  
 
Objective 2:  To design and implement an 8-week HCV treatment program 
utilizing the medication Mavyret for BAART Turk patients.  
 
Objective 3:  To achieve 100% uptake and success of the HCV treatment program 
at BAART Turk by all eligible HCV positive patients, as demonstrated by an 
attained SVR at 12 weeks.  
 
Objective 4: To achieve 85% staff satisfaction with the implementation of the 
project at BAART Turk. 
Objective 5: To achieve an overall 85% patient satisfaction with project 
effectiveness and implementation. 
 
B) Description of Intervention:  
1) Research to determine need for HCV treatment program in SF. 
2) Perform patient chart reviews to see who is eligible and appropriate for 
treatment. 
3) Provide patient education to the patients and the patient’s counselors regarding 
the HCV treatment program and what to expect (benefits of treatment, possible 
side effects that may be experienced, resources for HCV information, 
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prevention of reinfection, availability of provider support).  
4) Oversee the initiation, constant monitoring during treatment, and the 
completion of HCV treatment with proper blood work. 
5)   SVR12 determines if patient cured from HCV.  
C) How will this intervention change practice? Currently, there is no established 
HCV treatment program at BAART Turk. Treating these patients will positively 
impact the BAART Turk clinic and the overall healthcare system in a tremendous way 
by preventing and reducing health complications/comorbidities that may be associated 
with damage to the body due to HCV.  
D) Outcome measurements:  
Outcome 1: 90% of the participating providers at BAART will increase their 
knowledge related to HCV screening, assessment, treatment as evidenced by pre- 
and post-test surveys indicating scores of 90% and above. There will be a total of 
9 questions asked and will demonstrate knowledge about HCV treatment 
protocols and side effects. 
Outcome 2: Ten BAART patients will be identified, screened, assessed, and 
started on HCV treatment with Mavyret based on the identified and initiated 
HCV treatment protocol at BAART Turk.  
 
Outcome 3: At least 50% of selected patients who received treatment for HCV 
will complete their medication course of Mavyret and have an attained SVR12. 
 
Outcome 4: 85% of the providers will express satisfaction with the design and 
implementation of the HCV treatment program. 
 
Outcome 5: 85% of the patients treated will express satisfaction with the overall 




To qualify as an Evidence-based Change in Practice Project, rather than a Research Project, the 
criteria outlined in federal guidelines will be used:  
(http://answers.hhs.gov/ohrp/categories/1569)  
X   This project meets the guidelines for an Evidence-based Change in Practice Project as 
outlined in the Project Checklist (attached). Student may proceed with implementation. 
☐This project involves research with human subjects and must be submitted for IRB approval 
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before project activity can commence. 
Comments:   
EVIDENCE-BASED CHANGE OF PRACTICE PROJECT CHECKLIST * 
 
Instructions: Answer YES or NO to each of the following statements: 
Project Title:  
 
YES NO 
The aim of the project is to improve the process or delivery of care with 
established/ accepted standards, or to implement evidence-based change. There is 
no intention of using the data for research purposes. 
X  
The specific aim is to improve performance on a specific service or program and is 
a part of usual care.  ALL participants will receive standard of care. 
X  
The project is NOT designed to follow a research design, e.g., hypothesis testing 
or group comparison, randomization, control groups, prospective comparison 
groups, cross-sectional, case control). The project does NOT follow a protocol that 
overrides clinical decision-making. 
 X 
The project involves implementation of established and tested quality standards 
and/or systematic monitoring, assessment or evaluation of the organization to 
ensure that existing quality standards are being met. The project does NOT 
develop paradigms or untested methods or new untested standards. 
X  
The project involves implementation of care practices and interventions that are 
consensus-based or evidence-based. The project does NOT seek to test an 
intervention that is beyond current science and experience. 
X  
The project is conducted by staff where the project will take place and involves 
staff who are working at an agency that has an agreement with USF SONHP. 
X  
The project has NO funding from federal agencies or research-focused 
organizations and is not receiving funding for implementation research. 
X  
The agency or clinical practice unit agrees that this is a project that will be 
implemented to improve the process or delivery of care, i.e., not a personal 
research project that is dependent upon the voluntary participation of colleagues, 
students and/ or patients. 
X  
If there is an intent to, or possibility of publishing your work, you and supervising 
faculty and the agency oversight committee are comfortable with the following 
statement in your methods section:  “This project was undertaken as an Evidence-
based change of practice project at X hospital or agency and as such was not 
formally supervised by the Institutional Review Board.”  
X  
 
ANSWER KEY: If the answer to ALL of these items is yes, the project can be considered an 
Evidence-based activity that does NOT meet the definition of research.  IRB review is not 
required.  Keep a copy of this checklist in your files.  If the answer to ANY of these questions 
is NO, you must submit for IRB approval. 
 
*Adapted with permission of Elizabeth L. Hohmann, MD, Director and Chair, Partners Human 
Research Committee, Partners Health System, Boston, MA.   
 





STUDENT NAME (Please print): Annie Pedlar 
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Signature of Supervising Faculty Member (Chair): 
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Appendix B: Approval Letter 
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Establish HCV treatment 
program at BAART Turk Clinic 
Meet with Deb, MD, 
Brian, MD, and 
Cara, NP, counselors 
of patients 




Cara and I to meet with HCV 
experts, and people that are 
part of established HCV 
treatment programs 
Chart reviews; identify 
which patients are HCV 
Contact identified patients 
via: phone, in-person 
during PCP appt, mailed 
letter 
Determine if patient 
agrees to Rx. If yes, order 
appropriate blood work 
Order Mavyret from 
US BioServices 
Treat patient with 
Mavyret for 8/12 
weeks. Check viral 
load (VL) at 4,8,12 
weeks, SVR at 12 
weeks 
Pt education on 
prevention of 
reinfection, once SVR 
attained 












to the counselors of 
the patients via in-
person presentation 
and training  
Running head: HCV OUTREACH TREATMENT PROGRAM 
 
69 




 Hep C Pre- and Post-Evaluation 
 
1) What is hepatitis C? 
a. It is a bacterial infection of the liver 
b. It is a viral infection of the liver 
c. It is the same as Hepatitis A and B  
d. It is the same as HIV 
 
2) How do we confirm that someone is Hep C positive?  
a. Sputum sample 
b. Urine sample 
c. Blood work 
d. Skin biopsy 
 
3) What is the most common ‘mode of transmission’ of Hep C? 
a. Sexual intercourse 
b. Breastfeeding 
c. Needle sharing 
d. Someone who is infected and coughs on someone else (droplet) 
 
4) Here at BAART Turk, we will be treating clients living with Hep C with a medication 
called Mavyret. How long does the medication regimen last? 
a. 3 weeks 
b. 3 months 
c. 8-12 weeks 
d. 12-16 weeks 
 
5) What are common side effects of Mavyret (select all that apply)? 
a. Headache  
b. Nausea 
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Appendix E: Pre- and Post-Test Survey for Counselor Educational Session (cont.) 
6) To determine if Hep C has been cured after the completion of treatment, we do a blood 
test to check if there is a ___? 
a. Hep C Antibody (Ab) 
b. Hep B Ab 
c. Sustained Virologic Response (SVR) 
d. White blood cell count  
 
7) How can clients receive their Hep C medication (select all that apply)? 
a. DOT or window dosing 
b. Through an outside pharmacy 
c. It can be delivered directly to the client’s residence 
d. Take-home 
 
8) Which BAART Turk patients will we treat for Hep C?    
a. All patients who test positive for Hep C 
b. Patients who have a primary care provider outside of BAART Turk 
c. Patients who do not have a primary care provider  
d. Patients who have a primary care provider at BAART Turk 
 
9) What are complications of untreated Hep C (select all that apply)? 
a. Diabetes  
b. Liver cancer 
c. Ascites 
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Appendix F: SWOT Analysis 
STRENGTHS 
• Good cause- brings awareness and 
highlights the healthcare gap seen 
in San Francisco regarding the 
lack of access for high risk 
patients to receiving HCV 
treatment in the primary care 
setting. 
• Mavyret has few to no SE (should 
be tolerated well by all pt’s) 
• Window dosing (DOT very 
beneficial) 
• Staff NP, staff MD, and medical 
director have direct contact with 




• Identifying the insurance of each 
pt 
• Identifying patients who are 
HCV+ and VL+ 
• Obtaining blood work from 
patients (hard stick, not going to 
Quest, arriving at BAART too late 
in day and blood cannot be drawn 
by RN) 
• Lack of transportation to PCP 
visits and to have labs drawn 
• Pt demographics (homeless, no 
phone number or address) 
• Adherence to Rx 
• No incentives in budget 
OPPORTUNITIES 
• Out-reach to the HCV community 
who have limited or no access to 
healthcare 
• Reduction in liver disease in SF 
• Reduction in HCV rates by curing 
• Awareness of HCV in community 
(prevention methods) 
• Establish chronic disease 
initiatives at BAART Turk 
THREATS (things that cannot be 
controlled) 
• Homeless patients are unable to 
be contacted.  
• Not identifying all possible 
patients 
• Only SFHP creates monthly list of 
active patients…Anthem Blue 
Cross Medical and Medical do not 
generate such lists. How are we to 
contact these patients who may be 
eligible for Rx?  
• Medication does not come in time, 
difficulty in having meds received  
• Patient drops out of Rx due to SE, 
personal reasons  
• Pt moves away 
• Pt expires 
• Pt is no longer receiving 
methadone and does not want to 
return to BAART 
• QI panel management rolled out 
at BAART  
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Appendix G: Budget and Impact Analysis 
 
Description Amounts/Calculation Total 
STAFFING   
Project management  = $65/hour x 135 hours $8,775.00 
Project Oversite  = $120/hour x 10 
hours/week 
$62,400.00 
Consulting Physician = $120/hour x 5 hours/week $31,200.00 
TOTAL STAFFING  $102,375.00 
   
TRAINING   
Counselor 
Participants 
= $30/hour x 30 people x 1 
hour 
$900.00 
Site NP Support = $80/hour x 9 hours $720.00 
Printing In kind from BAART $0.00 
Pens $2 per box (x 1 box) $2.00 
Refreshments $20 (baked goods) $20.00 
TOTAL TRAINING  $1,642.00 
   
TRAVEL   
Mileage 40.8 miles/week x IRS rate 
54.5 cents  
$1,156.27 
Tolls $7/week x 52 weeks $364.00 
Parking $18/day x 52 weeks $936.00 
TOTAL TRAVEL  $2,456.27 

























Cost to US Healthcare System of HCV Infection 
 
Annual Cost of Advanced Liver 
Disease Caused By HCV 
$6.5 billion 
Average Lifetime Cost Per Individual 
Infected With HCV 
$64,490 
Estimated Number of Individuals with 
HCV in SF 
12,000  




Returns on Cost of BAART HCV Implementation Project 
 
Projected Annual Cost of Treating 
HCV in SF 
$13 million  
Projected Annual Savings of BAART 
HCV Project Intervention 
20% or $2.6 million 
Annual Cost of BAART HCV Project $106, 473 
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INFORMATION AUDIENCE TIME METHODS OF 
COMMUNICATION  
DNP Project Status DNP Chair 
MD at BAART 
NP at BAART 
DNP Student 
Weekly  Email 





MD at BAART 





In-person meetings  
Phone 
Barriers/Issues/Resolutions 
with DNP Project 
DNP Chair 
MD at BAART 





In-person meetings  
Phone 
Milestones to DNP Project  DNP Chair 
MD at BAART 
NP at BAART 
DNP Student 
Continuous  Email 
In-person meetings  
Phone 




Appendix I: GANTT Chart 
 
Project GANTT 
 2018 2019 
Task/description   
Meet with stakeholders Jan 2018  
Complete literature review, 
analyze available evidence, 
meet with appropriate HCV 
experts  
Jan-Feb 2018  
Conduct chart reviews and 
identify patients who 
qualify for treatment 
March-June 2018  
Provide education session to 
counselors 
April 2018  
Implementation of HCV 
treatment program at 
BAART 
June 2018  
Data collection and analysis October 2018 Jan-Feb 2019 
Dissemination of project 
results 
 Feb 2019 
Complete written DNP 
Project 
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Appendix J: BAART Staff Satisfaction Survey 
 
 
Thank you in advance for completing this survey! I value your honest thoughts, feelings, and 
experiences regarding the implementation of the Hepatitis C Treatment Program at BAART 
Turk.  
 




1) How sustainable and feasible do you feel the current model (policies and procedures) of 
the Hepatitis C Treatment program is at BAART?  
 







2)  How likely did the Hepatitis C Treatment Program at BAART contribute to its overall 
improvement of Hepatitis C patients?  
 






3) How likely is it that improvements and/or changes could be made to the current 
Hepatitis C Treatment Program model at BAART to make it better?  
 






If less than ‘3’, please state why: 
If less than ‘3’, please state why: 
If less than ‘5’, please state why: 
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Appendix K: BAART Patient Satisfaction Survey 
 
Thank you in advance for completing this survey! We value your thoughts, feelings, and 
experiences, and want to provide you the best care.  
 
Please use the numeric scale 1-5, ‘1’ being ‘highly dissatisfied’ and ‘5’ being ‘highly satisfied’ to 
rate your experience with the hepatitis C treatment program at BAART Turk.  
	
 
1) Were you satisfied with the medical provider care and counseling you received? 
 
1 2 3 4 5 
 
2) How satisfied did you feel about the ease of obtaining and receiving your hepatitis C 
treatment medications?  
 
1 2 3 4 5 
 
3) How satisfied were you with the cost of treatment? 
 
1 2 3 4 5 
 
4) How satisfied were you with the medication itself? (For example, did you experience any 
side effects that made it challenging for you to adhere to the treatment regimen?) 
 
1 2 3 4 5 
 
5) Did you overall feel satisfied about the result of your hepatitis C treatment? 
 
1 2 3 4 5 
 
6) Based on your satisfaction with the hepatitis C treatment program at BAART Turk, 
would you recommend this program to others?  
 
Yes   No 
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Cara Nalagan, FNP-C, and Annie Pedlar, DNP-FNP 
Student Intern
Objectives 
• Understand Hepatitis C (Hep C) basics
• List Hep C treatment process from start to finish
• Review how we (counselor and medical provider) will work 
together to:
-Get BAART clients treated for Hep C
-Support process 
• Learn client teaching points to prevent infection and/or re-
infection of Hep C
What is Hepatitis C?
• Hepatitis C is a virus (Hep C) that affects the liver and 
causes inflammation
-Hep C is transmitted through blood (e.g. sharing needles) 
• Hep C affects over 3 million people in the U.S. (Hep C 
Hope, 2015)
• In SF, there are an estimated 12,000 people who live with 
undiagnosed and untreated Hep C (End Hep C SF, 2017)
• Many of the people who are infected do not even know it!
There is no vaccine for HCV, but the good news is it can be treated and cured!
End Hep C SF, October 2017
Who is at Risk for Hep C?            How is it Transmitted?
Being born between the years of 1945-
1965 (Baby boomer) 
Men who have sex with men (MSM)
People living with HIV
Transgender women 
People with a history of incarceration 
Current or past IV drug use (most 
common mode of transmission)
Contact with infected blood or needles 
(tooth brush, razor, nail clippers)
Tattoos or body piercings using non-
sterile tools
Blood transfusion or organ transplants 
before 1992
How is Hep C NOT Spread?
Coughing 
Sneezing






Why are We NOT Aware We Have Hep C?
• For many, Hep C symptoms do not appear for 
years or even decades. 
• Many of us do not get tested because…
üWe do not know we are at risk
üThere is no vaccine for Hep C like there is for 
Hep A and B, therefore Hep C is off our radar. 
üIf your client is unable to be tested here, they 
can go to Glide to have a fingerstick blood test 
done to see if they have Hep C.
What are the Symptoms of Hep C?
• By the time symptoms appear, liver damage may have 
already occurred.
• After a long period of no treatment of Hep C, the person 
can go into liver failure and/or develop liver cancer, which 
is very difficult to reverse and treat, and ascites (fluid build-
up in abdomen). 
• Symptoms include: fever, fatigue, loss of appetite, 
nausea/vomiting, abdominal pain, dark urine, gray-colored 
bowel movements, joint pain, jaundice (yellowing of eyes 
and skin), dry or itchy skin, sleep disturbances, depression, 
“brain fog”. 
Hep C Treatment Process












20% of patients clear the virus on their own!World Hepatitis C Alliance, May 2014
*RNA = viral load
SCREENING
Has the Client Been SCREENED? 
• Yes, the client has been screened with the appropriate Hep
C blood test and has been diagnosed as Hep C positive.
• If a blood test has not been completed, it is really important 
that the Hep C blood test be done so that we can initiate 
treatment evaluation for the client. 
Does the Client Want TREATMENT? 
If the client wants and agrees to treatment of their Hep C, it 
needs to be determined who their insurance is and where 
their primary care home is. 
What if my Client has Hep C but Does Not Have 
Primary Care Here at BAART Turk?
ØClient has primary care home…
Primary care home at outside clinic: Tom Waddell, Curry 
Senior Center, SFGH, etc. 
-Notify BAART Turk NPs
-ROI signature to communicate w/client’s outside PCP
-NP to write referral letter for Hep C treatment for client’s 
PCP & offer DOT of Hep C medication
ØClient does NOT have primary care home…
No primary care home
No health insurance
• Contact Medi-Cal
• If none, enroll for San Francisco Health Plan
• Client to elect BAART Community Healthcare (Turk) as primary care home
• Client to enroll for primary care at BAART Turk with Lucy at Front Desk
ØClient does NOT have primary care home…CONTINUED
Has Medi-Cal, but no primary care home
• Confirm which health plan client has: Anthem Blue Cross or 
San Francisco Health Plan?
• Client to elect BAART Community Healthcare (Turk) as 
primary care home.



















Phone number is: (415)777-9992 OR (888)558-5858
Hours: Monday-Friday 8:30 AM-5:30 PM
There is also an email option available
Assessment Questions Prior to Treatment 
Evaluation
• Prior Hep C treatment experience?
• Current medications?
• Does the client have liver cirrhosis? 








• Prior to starting Hep C treatment: blood tests are needed to 
confirm diagnosis of Hep C, and to check for liver function 
and other viral co-infections (Hep A & B, HIV) for treatment 
evaluation. 
*This has proven to be most challenging*
• Blood drawn at:




• At BAART Turk, we will be treating clients with a 
medication called Mavyret, which treats the 6 genotypes of 
Hep C. 
• It is to be taken once daily (3 pills at one time), for every 
day for 8-12 weeks. 
Medication Side Effects
• There are very little side effects, the most common are 
headache and fatigue (Epocrates, 2018)
• Other potential side effects include: nausea and diarrhea
(Epocrates, 2018)
• Side effects disappear within the first 2 weeks after the 
medication is started
Importance of ADHERENCE to Medication Regimen
• Adherence to the medication regimen is KEY: Cure is 
achieved in >95% of patients with 8-12 weeks of 
medication therapy. 
• The best way to promote adherence is by direct observed 
therapy (DOT) or “window dosing” when the client is also 
receiving their daily methadone dose. 
• Clients w/methadone take-homes can receive Mavyret as 
take-homes, max: 2 weeks’ worth at a time.
• SUPPORT/ENCOURAGE CLIENTS TO DOSE DAILY
Checking for Cure: Follow-up Blood Test During 
Treatment
• Repeat blood test to check Hep C viral load:
• At week 4 of treatment
• At end of treatment (week 8 or 12)
Checking for Cure: SVR
6 months after treatment completion: 
• Blood test for sustained virologic response (SVR) confirms 
CURE 
• The client will always have a positive blood test result for 
the Hep C antibody (Ab), but the viral load (VL or RNA) will 
be undetectable.
Infection/Re-infection Prevention
• After successful treatment of Hep C, it is possible to 
become re-infected!
• It is very important that we, as the clients’ support system, 
provide education & resources about safe behavior to 
reduce the risk of Hep C transmission and re-infection.
Infection/Re-infection Prevention
• According to End Hep C SF (2017), “you can protect 
yourself and others from getting hepatitis C by getting 
tested, talking about your status, and injecting safely”. All of 
these actions can reduce your risk of contracting or 
passing the virus on to others. 
• *See pamphlets* 
THANK YOU!
QUESTIONS?








• End Hep C SF (August 2017). The rapidly changing landscape of HCV: 
updates and opportunities for SF providers to diagnose and cure HCV. 
Retrieved from endhepsf.org/wpcontent/uploads/2017/09/SF-HCV-
Prevalence-EstimateSummary_revised-8.17.pdf 
• Epocrates. (2018). Epocrates Plus (Version 18.3) [Mobile application 
software]. Retrieved from http://itunes.apple.com
• Gilead (August 2015). Forget me not. Retrieved from HepChope.com
• World Hepatitis Alliance (May 2014). How testing for hepatitis C works. 
Retrieved from https://twitter.com/jvlazarus/status/471939663742402560
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Appendix M: HCV Treatment Protocols 
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RN Algorithm: Patient Assessment for Treatment 
Readiness  















































































































































RN Algorithm: Patients Active on Treatment  
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Appendix N: Evidence Table 
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